Table I.
Patient characteristics in the control and treatment groups at the beginning (day 0) and after 1 month of current treatment (day 30).
| Control group | Treatment group | ||||
|---|---|---|---|---|---|
| Characteristics | Day 0 | Day 30 | Day 0 | Day 30 | P-value |
| Systolic BP (mmHg) | 123.0±1.8 | 123.5±1.9 | 119.8±2.5 | 120.1±2.4 | 0.43 |
| Diastolic BP (mmHg) | 79.9±1.0 | 79.2±1.0 | 79.2±1.1 | 78.6±1.4 | 0.89 |
| Total cholesterol (mmol/l) | 4.8±0.2 | 4.7±0.2 | 5.1±0.2 | 5.0±0.2 | 0.39 |
| LDL cholesterol (mmol/l) | 2.6±0.2 | 2.7±0.2 | 2.6±0.1 | 2.4±0.2 | 0.45 |
| HDL cholesterol (mmol/l) | 1.7±0.1 | 1.7±0.1 | 1.8±0.1 | 1.8±0.1 | 0.31 |
| Triglycerides (mmol/l) | 1.0±0.1 | 0.9±0.1 | 0.8±0.1 | 0.8±0.1 | 0.56 |
| Serum glucose (mmol/l) | 8.0±0.9 | 7.9±0.7 | 7.0±0.7 | 6.3±0.7 | 0.21 |
The treatment group received a combination of 10 mg fluvastatin and 20 mg valsartan daily while the control group received placebo for 30 days. Values are expressed as mean ± standard error of the mean (n=22 per group). BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein. The P-value refers to comparison among all four measured values of separate variables.